Switching on kinases: oncogenic activation of BRAF and the PDGFR family.
about
Cell signaling by receptor tyrosine kinasesERBB2 in cat mammary neoplasias disclosed a positive correlation between RNA and protein low expression levels: a model for erbB-2 negative human breast cancerOverexpression of platelet-derived growth factor receptor alpha in breast cancer is associated with tumour progressionTen things you should know about protein kinases: IUPHAR Review 14Recent applications of chemosensitivity tests for colorectal cancer treatmentThe role of suppressors of cytokine signalling in human neoplasmsActivation of tyrosine kinases by mutation of the gatekeeper threonineStructural Basis for c-KIT Inhibition by the Suppressor of Cytokine Signaling 6 (SOCS6) Ubiquitin LigasePrimary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumorHotspot mutations in KIT receptor differentially modulate its allosterically coupled conformational dynamics: impact on activation and drug sensitivityInsight on Mutation-Induced Resistance from Molecular Dynamics Simulations of the Native and Mutated CSF-1R and KITA network-based gene-weighting approach for pathway analysis.An in silico study of the molecular basis of B-RAF activation and conformational stability.Bi-directional SIFT predicts a subset of activating mutations.Tyrosine kinases in inflammatory dermatologic disease.A single amino acid substitution in the activation loop defines the decoy characteristic of VEGFR-1/FLT-1Leucine motif-dependent tyrosine autophosphorylation of type III receptor tyrosine kinases.The multifaceted role of curcumin in cancer prevention and treatment.Insight into molecular dynamics simulation of BRAF(V600E) and potent novel inhibitors for malignant melanomaDifferential effects of CSF-1R D802V and KIT D816V homologous mutations on receptor tertiary structure and allosteric communicationCorrelation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial.Targeting the mitogen-activated protein kinase cascade to treat cancer.Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer.Structure of extracellular signal-regulated kinase 2 in complex with ATP and ADP.KIT immunohistochemistry and mutation status in gastrointestinal stromal tumours (GISTs) evaluated for treatment with imatinib.Raf kinases: oncogenesis and drug discovery.Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance.Emerging drugs for the treatment of soft tissue sarcomas.The genomic landscape of response to EGFR blockade in colorectal cancer.Dabrafenib in an elderly patient with metastatic melanoma and BRAF V600R mutation: a case reportCRAF R391W is a melanoma driver oncogenePan-Cancer Analysis of Mutation Hotspots in Protein Domains.Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: clinical activity and biological correlationsIndividualized therapy for metastatic colorectal cancer.Potential biofluid markers and treatment targets for renal cell carcinoma.Novel targets in the treatment of advanced melanoma: new first-line treatment options.Personalized medicine in hematology - A landmark from bench to bedUsing molecular diagnostic testing to personalize the treatment of patients with gastrointestinal stromal tumors.Autoinhibition of the Ron receptor tyrosine kinase by the juxtamembrane domain.A new mechanism of BRAF activation in human thyroid papillary carcinomas.
P2860
Q24598357-F100FC52-B79E-4C8B-ADE9-6A4D40D47EBBQ24810389-01148F09-CF57-4F84-BAE0-1792C552DD9CQ24813774-904354C8-B467-4C20-B4B5-0D5A5A8171CFQ26849417-EA08B530-E800-44F6-BA34-013381B1DFD2Q26851075-D609ED57-1706-44B9-8E77-49E5AE9D1879Q27026783-240B7745-41CD-4396-8E99-95C1E7A95FA7Q27652166-B86F173D-D077-404D-8E84-C3B1A0023C18Q27665424-6B8B4EC3-6812-42AE-A19A-D336DE1B4C78Q27851455-DB3FE7AC-DFDE-4465-99C5-861E81E04741Q28541374-8DADD2DF-1D7B-4BC9-A02D-F4064BC10CA0Q28553167-2B8C7C01-4A0F-4CE2-B1A3-70061261C40FQ30506064-6CE3BF9B-33B8-4938-939E-8949DFA7C69BQ33485591-C7F60C4D-39FB-4B35-8E6A-59B4B8257B4BQ33518531-C1A2E058-5CDB-4CAC-90BF-7E4EA1470BEBQ34166503-6CC3D68F-96E0-4E7F-8DD6-FA47DD178812Q34333820-1AF566F6-6F5A-4737-A272-A6E56E3EBCC8Q34595463-9AC1DB77-675E-44BF-95AF-3F5B10B9F17CQ34667865-419CEA30-E0C0-4BEC-BB8D-F05184DB260EQ34669746-45973157-4922-49DB-B5D7-0CE6F694CDD4Q35168745-2E0BFC03-19AF-4BC4-BA57-40B98668941BQ35895558-8C118A65-6745-41DF-8EE7-1E1E3EC0FD39Q35968411-C79168E3-0246-403F-8849-AC524DE8372EQ36245376-41DB3CCE-5AA8-47B0-9555-03ACFC92C07FQ36433601-D7214692-F062-4DA9-9799-F0FB878E72EDQ36536625-4E1B9617-9766-4F73-BF4D-95636BEE3B92Q36559414-A6E4A65E-37DE-4AE5-B1B2-3BF32F78E4FDQ36589865-810E7946-61DB-4936-9167-7CF0E4D1D4A4Q36758596-D02FB697-5239-4C5C-96F8-8FC6E47BEC87Q36930106-A13135F9-D6D3-425B-A208-2D8BB761B4FDQ36960097-5403322B-C467-4C31-8BE4-34FEA1C31085Q36980239-C5CB11FD-7388-480D-A4AA-E176501F3A0EQ37170860-80114FC7-B101-4DB0-BCC8-12D73B18965CQ37326191-D62AC92E-98C3-4390-BB33-843CDC657A9EQ38092886-04564331-DA56-4683-B5E0-85B0A09DBDF9Q38094918-E6D65B57-57C7-4A12-9EC5-4384723070BDQ38095228-EBCCED7A-21EF-4913-A3D7-B6C532D4444BQ38263199-9585AECF-95C6-4ED1-9B6B-3B4C5228A165Q39186932-BE4B0D2F-571A-440C-90D0-4954A1A989E5Q39628474-9678F171-1688-4B07-8202-E7966169C29CQ40743581-C5D88210-E010-4698-A8D8-E7EE6270FF11
P2860
Switching on kinases: oncogenic activation of BRAF and the PDGFR family.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Switching on kinases: oncogenic activation of BRAF and the PDGFR family.
@en
Switching on kinases: oncogenic activation of BRAF and the PDGFR family.
@nl
type
label
Switching on kinases: oncogenic activation of BRAF and the PDGFR family.
@en
Switching on kinases: oncogenic activation of BRAF and the PDGFR family.
@nl
prefLabel
Switching on kinases: oncogenic activation of BRAF and the PDGFR family.
@en
Switching on kinases: oncogenic activation of BRAF and the PDGFR family.
@nl
P2093
P2860
P356
P1476
Switching on kinases: oncogenic activation of BRAF and the PDGFR family.
@en
P2093
Clifford D Mol
Nick J Dibb
Stephen M Dilworth
P2860
P2888
P304
P356
10.1038/NRC1434
P407
P577
2004-09-01T00:00:00Z
P6179
1022431788